Maudsley 15th Edition: What Changed from the 14th Edition?
Clinical Review

Maudsley 15th Edition: What Changed Between the 14th and 15th Editions?

Published 2025 10 min read
Doctor reviewing the Maudsley 15th edition psychiatry guidelines

The Maudsley Prescribing Guidelines in Psychiatry (MPG) is a highly respected handbook. Psychiatrists, pharmacists, and trainees worldwide use it daily. Recently, the highly anticipated Maudsley 15th edition arrived in 2025. Previously, the 14th edition was published in 2021. Both versions aim to give clinicians evidence-based advice on psychotropic medication. However, the latest release makes several notable changes. Therefore, below is a comprehensive comparison of the two editions. Furthermore, we summarize reader feedback and introduce Edubros’ courses to help you master this new material.

Context for the 14th Edition (2021)

Written During the COVID-19 Pandemic

First, it is important to understand the context of the previous book. In the preface to the 14th edition, David M. Taylor notes that the book was produced under the “extraordinary” circumstances of the COVID-19 pandemic. Consequently, this severely affected healthcare workers. Despite the difficult situation, the authors emphasised that optimal treatment of mental illness remained essential. They also thanked contributors who continued working under immense pressure.

Updates and New Sections in 2021

The 14th edition was thoroughly updated to incorporate influential research published since 2017. Moreover, it covered all major psychotropic drugs introduced between 2017 and 2021. Specifically, it expanded the guidelines by adding new sections on:

  • Management of agitated delirium
  • Psychotropics at the end of life
  • Intravenous psychotropic formulations
  • Intramuscular clozapine and weekly oral penfluridol

The editors noted that the book aims to provide practical prescribing advice. This advice is based on literature reviews, clinical experience, and expert contributions. Additionally, they acknowledged that some recommendations go beyond licensed indications. They also warned that dose information may become out-dated as new research emerges.

International Scope and Reader Feedback

Furthermore, the 14th edition tried to have worldwide utility while keeping a mild emphasis on UK practice. To achieve this, it included drugs widely used globally, even if they were not marketed in the UK. A reviewer from Pavilion Health Today praised the 14th edition for being highly detailed. The review highlighted useful sections on covert medication administration. However, the reviewer regretted that it did not come with an accompanying digital version.

What is New in the Maudsley 15th Edition (2025)?

The Maudsley 15th edition is part of the growing Maudsley guideline series. David M. Taylor explains in the preface that the authors wanted to avoid repetition. Therefore, they removed or shortened some topics that had been covered in companion volumes. Key changes include the following:

Removed or Shortened Sections

To streamline the book, sections on delirium, psychotropics in surgery, and alternative routes of antidepressant administration were removed. In addition, the section on stopping psychotropics was significantly reduced.

Exciting New Sections in the Maudsley 15th Edition

The space freed by trimming overlapping content allowed the Maudsley 15th edition to add vital new sections. Specifically, it now covers premenstrual syndrome, menopause, gambling disorder, adult ADHD, and relational aspects of prescribing practice. Consequently, these additions address previously under-discussed issues such as reproductive health and behavioural addictions.

Acknowledging Wider Debates on Medication

Interestingly, the preface recognises a “growing antipathy towards the use of psychotropic drugs.” However, it clarifies that the guidelines assume a decision to prescribe has already been made. The authors explicitly state that drug treatment is not always the best option. Ultimately, their goal is to optimise prescribing rather than simply promote medication.

Expanded Scope Despite Trimming

Even though some material was moved to other books, the Maudsley 15th edition is described as having a greater scope than the previous edition. The authors tried to be “economic with words and references.” Nevertheless, they acknowledge that the new edition is heavier because it remains the definitive “big MPG”. Because of these changes, the text is more focused and responds directly to current clinical needs.

Comparing the 14th and Maudsley 15th Edition

Aspect 14th Edition (2021) Maudsley 15th Edition (2025)
Context Written during the COVID‑19 pandemic; updates research since 2017. Published as part of the wider Maudsley series; aims to reduce repetition.
Major Updates Added sections on agitated delirium, end‑of‑life psychotropic use, and intramuscular clozapine. Removed delirium/surgery sections; added PMS, menopause, gambling disorder, and adult ADHD.
Scope & Emphasis Expanded to include new drugs used worldwide while retaining a UK focus. Even after trimming overlapping topics, the scope is broader than the 14th edition.
Guiding Philosophy Provides practical, evidence‑based advice; acknowledges off‑label recommendations. Stresses that prescribing decisions should already be made; seeks to optimise practices.
Study Resource

Master the Maudsley 15th Edition with Edubros

Reading the updated guidelines can be challenging. This is especially true for students preparing for exams. Therefore, Edubros offers an online course – Maudsley Made Easy 3.0 – that simplifies the Maudsley 15th edition and adds interactive learning tools. Core features include:

  • A powerful search function and drug navigator.
  • Interactive notes, summary tables, and chapter‑wise MCQs.
  • Full mock exams designed for medical students, psychiatric nurses, and practising psychiatrists.

In short, this course transforms the dense material of the guidelines into digestible lessons. Consequently, it helps bridge the gap between reading and applying the guidelines clinically.

Explore More Recommended Psychiatry Courses

If you are preparing for major psychiatric examinations, Edubros provides comprehensive, high-yield courses tailored to your needs:

High-Yield Exam Specifics for the Maudsley 15th Edition

The new sections in the Maudsley 15th edition cover premenstrual syndrome (PMS), menopause, gambling disorder, adult ADHD, and relational aspects of prescribing. Below are concise clinical pearls drawn from official NICE guidance to help candidates prepare for exam questions.

Premenstrual Syndrome (PMS) Updates

  • Confirm the diagnosis: NICE and RCOG guidance recommend women keep a symptom diary over at least two menstrual cycles. This confirms symptoms occur in the luteal phase.
  • First‑choice treatments: SSRIs or SNRIs are effective for severe PMS. They can be taken daily or during the luteal phase.
  • Hormonal options: Combined oral contraceptives (containing drospirenone) can improve symptoms. Furthermore, oestrogen patches with a progestogen relieve symptoms.
  • Severe/refractory PMS: GnRH analogues may be used. However, this induces reversible menopause and requires add-back hormone therapy.

Menopause and Psychotropic Prescribing

  • HRT is first‑line: Mood changes are caused by fluctuating hormones. Therefore, HRT (oestrogen ± testosterone) is the most effective treatment.
  • Antidepressants are NOT first‑line: Guidelines strongly warn against using antidepressants as first-line for menopausal low mood due to a lack of evidence.
  • SSRIs/SNRIs for vasomotor symptoms: Low‑dose SSRIs (e.g., citalopram) may reduce hot flushes if HRT is contraindicated.

Adult ADHD Guidelines

  • First‑line medications: NICE NG87 states adults should be offered lisdexamfetamine or methylphenidate. These are off-label for adults but evidence-supported.
  • Switching strategies: If a 6‑week trial of methylphenidate fails, switch to lisdexamfetamine. Conversely, switch back if needed.
  • Second‑line options: Atomoxetine is offered only if stimulants fail. Do not prescribe guanfacine or antipsychotics without specialist advice.
  • Practical considerations: Modified‑release stimulants improve adherence and lower misuse risk.

Gambling Disorder Treatments

  • Psychological therapy is first‑line: Antidepressants are no better than a placebo for this condition.
  • Naltrexone as an adjunct: Opioid antagonists are recommended only for people who have not responded to psychological therapy. A specialist must initiate this.
  • Other agents: Mood stabilisers and atypical antipsychotics are NOT recommended due to very low-quality evidence.

Relational Aspects of Prescribing

  • Multi‑factor influences: Prescribing is affected by clinician factors (confidence), patient factors (expectations), and context factors (short appointments).
  • Exam tip: Always engage patients in shared decision‑making. Explore their expectations and acknowledge non‑pharmacological strategies.